Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.

HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.

Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.

Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.

Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.

A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.

Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.